PRESS RELEASE published on 01/09/2025 at 17:35, 1 year 5 months ago Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment Abivax achieves key milestone in Phase 3 ABTECT trial enrollment with 82% of target participants enrolled for evaluating obefazimod in ulcerative colitis, aiming for NDA submission by H2 2026 Abivax Obefazimod Ulcerative Colitis Phase 3 ABTECT Trial
BRIEF published on 12/23/2024 at 22:10, 1 year 5 months ago Abivax Announces Board Resignation Abivax Obefazimod Board Resignation Truffle Capital Philippe Pouletty
PRESS RELEASE published on 12/23/2024 at 22:05, 1 year 5 months ago Abivax Announces a Change to the Composition of its Board of Directors Abivax announces a change in its Board of Directors composition as Dr. Philippe Pouletty resigns due to new appointment. The company expresses gratitude for his contributions Board Of Directors Resignation Abivax Therapeutics Dr. Philippe Pouletty
BRIEF published on 12/18/2024 at 18:05, 1 year 5 months ago ABIVAX: Share capital and voting rights as of November 30, 2024 Euronext Paris Share Capital Voting Rights Abivax Investment
BRIEF published on 11/27/2024 at 18:05, 1 year 6 months ago ABIVAX: Update of Share Capital and Voting Rights Euronext Paris Share Capital Voting Rights Abivax Financial Transparency
BRIEF published on 11/19/2024 at 22:35, 1 year 6 months ago Abivax Launches ATM Program on Nasdaq Common Shares Biotechnology Funding Nasdaq ATM Program
PRESS RELEASE published on 11/19/2024 at 22:30, 1 year 6 months ago Abivax Establishes an At-the-Market (ATM) Program on Nasdaq Abivax establishes an At-the-Market (ATM) Program on Nasdaq, allowing issuance and sale of ordinary shares to raise up to $150 million. Implementation involves Piper Sandler & Co. as sales agent Ordinary Shares Abivax Nasdaq ATM Program Piper Sandler
BRIEF published on 11/14/2024 at 22:06, 1 year 6 months ago Abivax Releases Q3 2024 Financial Results Financial Results Biotechnology Abivax Ulcerative Colitis Q3 2024
PRESS RELEASE published on 11/14/2024 at 22:01, 1 year 6 months ago Abivax presents third quarter 2024 key financial information Abivax presents key financial information for the third quarter of 2024. The company announced updates on operational goals and debt status. Details on Abivax's cash and principal debt outstanding are provided Financial Information Abivax Quarter Results Clinical-stage Biotechnology Debt Status
BRIEF published on 11/13/2024 at 22:06, 1 year 6 months ago Abivax Appoints Mark Stenhouse as Observer and Strategic Advisor Biotechnology Abivax Obefazimod Appointment Mark Stenhouse
Published on 06/10/2026 at 14:30, 5 hours 54 minutes ago Agassi Sports Entertainment Signs Tennis Coaching Icon Darren Cahill to Expand Global Coaching, Content and Technology Initiatives
Published on 06/10/2026 at 14:30, 5 hours 54 minutes ago Ondas to Launch LADOS, a Layered Autonomous Defense Operational C2 Layer, at Eurosatory 2026
Published on 06/10/2026 at 13:00, 7 hours 24 minutes ago Galway Metals Reports 5.0 g/t Gold over 10.85 Metres at North Deposit and Continues to Intersect Gold in Northern Extension
Published on 06/10/2026 at 13:00, 7 hours 24 minutes ago Jaguar Mining Inc. Accelerates 5-Year Exploration Plan with Tier 1 Drilling Partnerships
Published on 06/10/2026 at 20:11, 13 minutes ago EQS-Adhoc: EDAG Engineering Group AG: Board of Directors resolves on capital measures to strengthen capital base
Published on 06/10/2026 at 18:39, 1 hour 45 minutes ago EQS-Adhoc: Kontron AG: Ad hoc announcement / Ennoconn Corporation intends to launch a mandatory takeover offer to Kontron AG shareholders
Published on 06/10/2026 at 18:20, 2 hours 4 minutes ago EQS-WpÜG: Takeover Offer / Target company: Hugo Boss AG; Bidder: Frasers Group plc
Published on 06/10/2026 at 18:03, 2 hours 21 minutes ago Kapsch TrafficCom AG presents preliminary results for 2025/26 and adapts its financial calendar.
Published on 06/10/2026 at 18:00, 2 hours 24 minutes ago Private Equity Holding AG: Net Asset Value as of May 31, 2026
Published on 06/10/2026 at 18:29, 1 hour 55 minutes ago ICADE – PR – OUTCOME OF THE COMBINED GENERAL MEETING HELD ON JUNE 10 2026
Published on 06/10/2026 at 17:40, 2 hours 44 minutes ago Report on share repurchases from 3 to 9 June 2026
Published on 06/10/2026 at 07:00, 13 hours 24 minutes ago Acceleration of Museum Studio's international expansion
Published on 06/09/2026 at 19:30, 1 day ago MONTHLY INFORMATION CONCERNING THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES
